Leap therapeutics announces initiation of new dkn-01 clinical trials in gastric cancer, colorectal cancer and endometrial cancer

Randomized controlled first-line gastric cancer trial of dkn-01 plus tislelizumab and chemotherapy in collaboration with beigene leap to host r&d day today at 12:00 p.m. et cambridge, mass.

LPTX Ratings Summary

LPTX Quant Ranking